Strong Bonds Stand the Test of Time

Geovanna, a ZEVASKYN patient at age 8

Strong Bonds Stand the Test of Time

Durable wound healing with a single surgical application—even in tough
RDEB wounds1*

  • 81% of ZEVASKYN-treated wounds (35/43) achieved 50% or more healing vs 16% of matched control wounds (7/43) at week 24 in a Phase 3 study (P<0.0001)†
View long-term follow-up images Right-open Right-open
Link to: How ZEVASKYN Works
Immunofluorescent image of anchoring fibril formation

How ZEVASKYN works

Learn how patients’ own skin cells are gene-modified to create cellular sheets

Link to: Efficacy
Before ZEVASKYN treatment baseline wound

Proven wound healing

See ZEVASKYN healing results in chronic RDEB wounds

Link to: Support & Resources
Strong Together Network collage of patients and caregivers

Help patients connect

Through the Strong Together Network, learn about experiences with ZEVASKYN from patients living with RDEB and their caregivers

Link to: Support & Resources
Abeona Assist patient navigator

All-in-one support

From personalized help to comprehensive resources, Abeona Assist is here for your patients

Jessica holding her daughter, a ZEVASKYN-treated patient

When the nurse and doctor took off the bandage and I saw that new skin, when I saw it I just cried.”

Discover Jessica's journey through her daughter's treatment Right-open Right-open
  • RDEB=recessive dystrophic epidermolysis bullosa.
  • *Wounds treated had remained open for at least 6 months.
  • †Investigator-assessed; multi-center, randomized, intrapatient-controlled study with 43 ZEVASKYN-treated wounds vs 43 matched control wounds in 11 patients with RDEB.

To find a ZEVASKYN Qualified Treatment Center, ask questions, or refer your patients, call Abeona Assist at 1-855-ABEONA-1 (1-855-223-6621) or visit abeonaassist.com.

Call now Right-open Right-open
Follow a manual added link
Abeona Assist™ logo with tagline “Your partner in navigation and support”
About RDEB Right-open Right-open

Reference: 1. ZEVASKYN™ (prademagene zamikeracel) Prescribing Information. Cleveland, OH: Abeona Therapeutics Inc; 2025.

Indication

ZEVASKYN™ (prademagene zamikeracel) is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).

Important Safety Information

  • Severe hypersensitivity reactions to vancomycin, amikacin, or product excipients may occur with ZEVASKYN application. Monitor for signs and symptoms of hypersensitivity reactions such as itching, swelling, hives, difficulty breathing, runny nose, watery eyes, nausea, and in severe cases, anaphylaxis and treat according to standard clinical practice.
  • Retroviral vector (RVV)-mediated insertional oncogenesis may potentially occur after treatment with ZEVASKYN. Monitor patients lifelong after treatment for the development of malignancies. In the event that a malignancy occurs, contact Abeona Therapeutics Inc. at 1-844-888-2236.
  • Transmission of infectious disease or agents may occur with ZEVASKYN because it is manufactured using human- and bovine-derived reagents, which are tested for human and animal viruses, bacteria, fungi, and mycoplasma before use. These measures do not eliminate the risk of transmitting these or other infectious diseases or agents.
  • The most common adverse reactions (incidence ≥5%) were procedural pain and pruritus.

Please see full Prescribing Information.

Indication

ZEVASKYN™ (prademagene zamikeracel) is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).

Important Safety Information

  • Severe hypersensitivity reactions to vancomycin, amikacin, or product excipients may occur with ZEVASKYN application. Monitor for signs and symptoms of hypersensitivity reactions such as itching, swelling, hives, difficulty breathing, runny nose, watery eyes, nausea, and in severe cases, anaphylaxis and treat according to standard clinical practice.
  • Retroviral vector (RVV)-mediated insertional oncogenesis may potentially occur after treatment with ZEVASKYN. Monitor patients lifelong after treatment for the development of malignancies. In the event that a malignancy occurs, contact Abeona Therapeutics Inc. at 1-844-888-2236.
  • Transmission of infectious disease or agents may occur with ZEVASKYN because it is manufactured using human- and bovine-derived reagents, which are tested for human and animal viruses, bacteria, fungi, and mycoplasma before use. These measures do not eliminate the risk of transmitting these or other infectious diseases or agents.
  • The most common adverse reactions (incidence ≥5%) were procedural pain and pruritus.

Please see full Prescribing Information.

Abeona Therapeutics® logo

ZEVASKYN, Abeona Assist, and the related logos are trademarks of Abeona Therapeutics Inc. All other trademarks are the property of their respective owners.

© 2025 Abeona Therapeutics Inc. All rights reserved. US-COM-ZEV-240021  05/25